Kevin Fox, MD
Ultima Vez Modificado: 9 de junio del 2002
Dear OncoLink "Ask The Experts,"
Kevin Fox, MD Assistant Director, Clinical Affairs and Associate Professor of Hematology/Oncology at the Abramson Cancer Center of the University of Pennsylvania responds:
It can be frustrating to the individual observer when looking at overall mortality figures. Overall mortality from breast cancer has dropped, but only by a little bit. The two most likely reasons are early detection from increased use of mammography, and from more effective drug therapies (adjuvant therapies) for patients with early stages of disease. By catching breast cancer at an earlier stage, we should be able to impact survival over time, but this may take many years to prove. Similarly, with the addition of new adjuvant therapies and broader distribution and availability, we hope to see this trend continue.
Oct 20, 2010 - Postmenopausal estrogen-plus-progestin therapy not only results in an increased incidence of invasive breast cancers but also in more node-positive cancers and an increased mortality rate, according to an analysis published in the Oct. 20 issue of the Journal of the American Medical Association.
Jun 7, 2011